Forbes March 5, 2024
Two weeks ago, the Food and Drug Administration approved Xolair (omalizumab) for immunoglobulin E-mediated food allergy in certain adults and children one year or older for the reduction of allergic reactions. Xolair’s sponsors Roche and Novartis have been working on getting coverage for the product in the new indication. Given the high price of the drug and its need to be used indefinitely it can be a challenge to convince insurers.
Xolair is the first FDA-approved medication to reduce allergic reactions to more than one type of food after accidental exposure. Importantly, this includes reducing the risk of anaphylaxis that may occur with accidental exposure to one or more foods.
According to the Centers for Disease Control and Prevention, approximately...
Today's Sponsors
Today's Sponsor